Literature DB >> 21184132

CD133+ niches and single cells in glioblastoma have different phenotypes.

Karina Christensen1, Henrik Daa Schrøder, Bjarne Winther Kristensen.   

Abstract

Putative CD133(+) brain tumor stem cells have been shown to be located in niches and as single cells. This is the first study providing insight into the different phenotypes of CD133(+) cells in glioblastoma according to localization. Paraffin sections were stained by double immunofluorescence with CD133 and the candidate stem cell markers Sox2, Bmi-1, EGFR, podoplanin and nestin, the proliferation marker Ki67 and the endothelial cell markers CD31, CD34, and VWF. Cell counting showed that the CD133(+) cells in the niches had a significantly higher expression of Sox2, EGFR and nestin compared to CD133(+) single cells, but only a 3% Ki67 labeling index versus 14% found for CD133(+) single cells. Only low endothelial cell marker expression was found in the niches or the CD133(-) tumor areas, while 43% CD133(+)/CD31(+) and 25% CD133(+)/CD34(+) single cells were found. CD133(+) blood vessels within CD133(+) niches were less proliferative and more often Bmi-1(+) than CD133(+) blood vessels outside niches. In conclusion, different CD133(+) cell phenotypes exist according to the in situ localization, and also the phenotype of CD133(+) blood vessels vary according to the localization. CD133(+) niches contain stem-like cells with a lower proliferation index than CD133(+) single cells, which have an endothelial differentiation profile suggesting a role in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184132     DOI: 10.1007/s11060-010-0488-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  84 in total

1.  Vascular niche for adult hippocampal neurogenesis.

Authors:  T D Palmer; A R Willhoite; F H Gage
Journal:  J Comp Neurol       Date:  2000-10-02       Impact factor: 3.215

2.  Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.

Authors:  Anna V Molofsky; Ricardo Pardal; Toshihide Iwashita; In-Kyung Park; Michael F Clarke; Sean J Morrison
Journal:  Nature       Date:  2003-10-22       Impact factor: 49.962

3.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

Authors:  M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

Authors:  U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  Expression of PECAM-1/CD31 isoforms in human brain gliomas.

Authors:  F Aroca; W Renaud; C Bartoli; C Bouvier-Labit; D Figarella-Branger
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

6.  Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas.

Authors:  J Haapasalo; A Mennander; P Helen; H Haapasalo; J Isola
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

7.  Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.

Authors:  Kazuhiko Mishima; Yukinari Kato; Mika Kato Kaneko; Ryo Nishikawa; Takanori Hirose; Masao Matsutani
Journal:  Acta Neuropathol       Date:  2006-04-05       Impact factor: 17.088

8.  Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

Authors:  Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 9.  The cancer stem cell-vascular niche complex in brain tumor formation.

Authors:  Anand Veeravagu; Simon R Bababeygy; M Yashar S Kalani; Lewis C Hou; Victor Tse
Journal:  Stem Cells Dev       Date:  2008-10       Impact factor: 3.272

10.  Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.

Authors:  Margarita Sánchez-Beato; Esther Sánchez; Joaquín González-Carreró; Manuel Morente; Ana Díez; Lydia Sánchez-Verde; María Carmen Martín; Juan C Cigudosa; Miguel Vidal; Miguel A Piris
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

View more
  29 in total

Review 1.  An epigenetic gateway to brain tumor cell identity.

Authors:  Stephen C Mack; Christopher G Hubert; Tyler E Miller; Michael D Taylor; Jeremy N Rich
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

Review 2.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

3.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins.

Authors:  Vashendriya V V Hira; Jill R Wormer; Hala Kakar; Barbara Breznik; Britt van der Swaan; Renske Hulsbos; Wikky Tigchelaar; Zbynek Tonar; Mohammed Khurshed; Remco J Molenaar; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2018-01-03       Impact factor: 2.479

5.  Cancer stem cells: the challenges ahead.

Authors:  Jan Paul Medema
Journal:  Nat Cell Biol       Date:  2013-04       Impact factor: 28.824

Review 6.  Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment.

Authors:  Edjah Kweku-Ebura Nduom; Costas George Hadjipanayis; Erwin G Van Meir
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 7.  Sox2: regulation of expression and contribution to brain tumors.

Authors:  Sheila Mansouri; Romina Nejad; Merve Karabork; Can Ekinci; Ihsan Solaroglu; Kenneth D Aldape; Gelareh Zadeh
Journal:  CNS Oncol       Date:  2016-05-27

8.  NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.

Authors:  Junsheng Fu; Mariana Rodova; Rajesh Nanta; Daniel Meeker; Peter J Van Veldhuizen; Rakesh K Srivastava; Sharmila Shankar
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

Review 9.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

10.  Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.

Authors:  Balint Otvos; Daniel J Silver; Erin E Mulkearns-Hubert; Alvaro G Alvarado; Soumya M Turaga; Mia D Sorensen; Patricia Rayman; William A Flavahan; James S Hale; Kevin Stoltz; Maksim Sinyuk; Qiulian Wu; Awad Jarrar; Sung-Hak Kim; Paul L Fox; Ichiro Nakano; Jeremy N Rich; Richard M Ransohoff; James Finke; Bjarne W Kristensen; Michael A Vogelbaum; Justin D Lathia
Journal:  Stem Cells       Date:  2016-05-27       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.